Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes
The product was removed from refrigerated storage for an extended period of time.Recall Initiation Date: April 9, 2025Link: FDA Enforcement Report Facility Inspections FDA Warning Letters ProRx, LLC Type: Compounding pharmacy and FDA-registered outsourcing facilityFDA Department issuing Warning: Center for Drug Evaluation and Research (CDER)Warning Letter Date: January 15, 2025Facility Location: Exton, PennsylvaniaInspection Dates: July 15, 2024, to August 2, 2024
Among respondents, 53% reported as Millennials, 26% reported as Gen X, 13% reported as Gen Z, and 8% reported as Baby Boomers
Signos de hipoglucemia: Pueden manifestarse de forma repentina e incluyen sudoracin fra, palidez, dolor de cabeza, taquicardia, sensacin de hambre o nuseas, visin borrosa, somnolencia, fatiga, nerviosismo, ansiedad, confusin, problemas para concentrarse y temblores.
doi: 10.3389/fendo.2020.00178 [DOI] [PMC free article] [PubMed] [Google Scholar] 16.Mann JFE, Fonseca VA, Poulter NR, et al
Identical Pharmacy eligibility criteria to SGLT-2 inhibitor Empagliflozin, but funding is either or Some patient could benefit from both SGLT-2 inhibitor and GLP-1 agonists
